Pfizer begins Phase 3 study of quadrivalent modRNA influenza vaccine
It is the first Phase 3 study to evaluate the efficacy, safety, tolerability and immunogenicity of an mRNA-based…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
15 Sep 22
It is the first Phase 3 study to evaluate the efficacy, safety, tolerability and immunogenicity of an mRNA-based…
08 Sep 22
The late-stage trial evaluated the Trop-2 directed antibody-drug conjugate in comparison to TPC chemotherapy in 543 patients having…
30 Aug 22
Patients receiving treatment with cemdisiran experienced clinically significant decreases in their 24-hour urine protein to creatinine ratio when…
24 Aug 22
In the updated analysis, the Pfizer-BioNTech Covid-19 vaccine showed 73.2% efficacy in children aged six months to four…
16 Aug 22
The primary endpoint of the Phase III CANOPY-A study was disease-free survival (DFS) versus placebo
12 Aug 22
Pfizer intends to submit a supplemental Biologics License Application (sBLA) with the FDA by the end of this…
28 Jul 22
The Phase 2 trial of BNT162b5 will enrol around 200 participants, aged between 18 and 55 years, who…
25 Jul 22
PH94B is designed to regulate the olfactory-amygdala neural circuits of fear and anxiety, but it did not achieve…
01 Jul 22
The US FDA has paused new enrolment in the US and told the participants who have been enrolled…
17 Jun 22
In the study, crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation…